{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:13:02Z","timestamp":1790241182761,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T00:00:00Z","timestamp":1590364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T00:00:00Z","timestamp":1590364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s00277-020-04100-8","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T21:02:30Z","timestamp":1590440550000},"page":"1605-1613","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["R-CHOP appears to be the best first-line treatment for second primary diffuse large B cell lymphoma: a cancer registry study"],"prefix":"10.1007","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0507-1740","authenticated-orcid":false,"given":"T.","family":"Systchenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Defossez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Guidez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Puyade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Debiais-delpech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Dreyfus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Machet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Delwail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ingrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,25]]},"reference":[{"key":"4100_CR1","first-page":"104","volume":"6","author":"International Association of Cancer Registries","year":"2005","unstructured":"International Association of Cancer Registries (2005) International rules for multiple primary cancers. Asian Pac J Cancer Prev 6:104\u2013106","journal-title":"Asian Pac J Cancer Prev"},{"key":"4100_CR2","volume-title":"Cancer registration handbook","author":"S Ferreti","year":"2010","unstructured":"Ferreti S, Giacomin A, the AIRTUM workgroup (2010) Cancer registration handbook. Inferenze, Milano"},{"key":"4100_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000172","volume":"2","author":"A Vogt","year":"2017","unstructured":"Vogt A, Schmid S, Heinimann K, Frick H, Herrmann C, Cerny T, Omlin A (2017) Multiple primary tumours: challenges and approaches, a review. ESMO Open 2:e000172. https:\/\/doi.org\/10.1136\/esmoopen-2017-000172","journal-title":"ESMO Open"},{"key":"4100_CR4","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s10552-013-0203-3","volume":"24","author":"HK Weir","year":"2013","unstructured":"Weir HK, Johnson CJ, Thompson TD (2013) The effect of multiple primary rules on population-based cancer survival. Cancer Causes Control 24:1231\u20131242. https:\/\/doi.org\/10.1007\/s10552-013-0203-3","journal-title":"Cancer Causes Control"},{"key":"4100_CR5","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1002\/cncr.30164","volume":"122","author":"N Donin","year":"2008","unstructured":"Donin N, Filson C, Drakaki A, Tan HJ, Castillo A, Kwan L, Litwin M, Chamie K (2008) Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008. Cancer 122:3075\u20133086. https:\/\/doi.org\/10.1002\/cncr.30164","journal-title":"Cancer"},{"issue":"Suppl5","key":"4100_CR6","doi-asserted-by":"publisher","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","volume":"26","author":"H Tilly","year":"2015","unstructured":"Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, Walewski J, Andr\u00e9 M, Johnson PW, Pfreundschuh M, Ladetto M, ESMO Guidelines Committee (2015) Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl5):v116\u2013v125. https:\/\/doi.org\/10.1093\/annonc\/mdv304","journal-title":"Ann Oncol"},{"key":"4100_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235\u2013242. https:\/\/doi.org\/10.1056\/NEJMoa011795","journal-title":"N Engl J Med"},{"key":"4100_CR8","volume-title":"International classification of diseases for oncology","author":"A Fritz","year":"2000","unstructured":"Fritz A, Percy C, Jack A et al (2000) International classification of diseases for oncology, 3rd edn. World Health Organisation, Geneva","edition":"3"},{"key":"4100_CR9","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1182\/blood-2006-11-051672","volume":"110","author":"LM Morton","year":"2007","unstructured":"Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadi\u00e9 M, Spinelli JJ, Costantini AS, R\u00fcdiger T, Scarpa A, Zheng T, Weisenburger DD (2007) Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 110:695\u2013708. https:\/\/doi.org\/10.1182\/blood-2006-11-051672","journal-title":"Blood"},{"issue":"Suppl5","key":"4100_CR10","doi-asserted-by":"publisher","first-page":"v91","DOI":"10.1093\/annonc\/mdw175","volume":"27","author":"U Vitolo","year":"2016","unstructured":"Vitolo U, Seymour JF, Martelli M, Illerhaus G, Illidge T, Zucca E, Campo E, Ladetto M, ESMO Guidelines Committee (2016) Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(Suppl5):v91\u2013v102. https:\/\/doi.org\/10.1093\/annonc\/mdw175","journal-title":"Ann Oncol"},{"issue":"Suppl3","key":"4100_CR11","doi-asserted-by":"publisher","first-page":"iii544","DOI":"10.1093\/annonc\/mdx413","volume":"29","author":"C Buske","year":"2018","unstructured":"Buske C, Hutchings M, Ladetto M et al (2018) ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. Ann Oncol 29(Suppl3):iii544\u2013iii562. https:\/\/doi.org\/10.1093\/annonc\/mdx413","journal-title":"Ann Oncol"},{"key":"4100_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, M\u00fcller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275\u2013282. https:\/\/doi.org\/10.1182\/blood-2003-05-1545","journal-title":"Blood"},{"key":"4100_CR13","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med 329:987\u2013994. https:\/\/doi.org\/10.1056\/NEJM199309303291402","journal-title":"N Engl J Med"},{"key":"4100_CR14","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM (2007) The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857\u20131861. https:\/\/doi.org\/10.1182\/blood-2006-08-038257","journal-title":"Blood"},{"key":"4100_CR15","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3324\/haematol.2016.152918","volume":"102","author":"S Le Guyader-Peyrou","year":"2017","unstructured":"Le Guyader-Peyrou S, Orazio S, Dejardin O, Maynadi\u00e9 M, Troussard X, Monnereau A (2017) Factors related to the relative survival of patients with diffuse large B-cell lymphoma in a population-based study in France: does socio-economic status have a role? Haematologica 102:584\u2013592. https:\/\/doi.org\/10.3324\/haematol.2016.152918","journal-title":"Haematologica"},{"key":"4100_CR16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1756-9966-28-116","volume":"28","author":"Y Terada","year":"2009","unstructured":"Terada Y, Nakamae H, Aimoto R, Kanashima H, Sakamoto E, Aimoto M, Inoue E, Koh H, Nakane T, Takeoka Y, Ohsawa M, Koh KR, Yamane T, Nakao Y, Ohta K, Mugitani A, Teshima H, Hino M (2009) Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma. J Exp Clin Cancer Res 28:116. https:\/\/doi.org\/10.1186\/1756-9966-28-116","journal-title":"J Exp Clin Cancer Res"},{"key":"4100_CR17","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00277-010-0956-7","volume":"89","author":"T Hirakawa","year":"2010","unstructured":"Hirakawa T, Yamaguchi H, Yokose N, Gomi S, Inokuchi K, Dan K (2010) Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma. Ann Hematol 89:897\u2013904. https:\/\/doi.org\/10.1007\/s00277-010-0956-7","journal-title":"Ann Hematol"},{"key":"4100_CR18","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/bjh.13619","volume":"173","author":"TA Eyre","year":"2016","unstructured":"Eyre TA, Salisbury R, Eyre DW, Watson C, Collins GP, Hatton CS (2016) Results of a large retrospective analysis of the effect of intended dose intensity of R-CHOP on outcome in a cohort of consecutive, unselected elderly patients with de novo diffuse large B cell lymphoma. Br J Haematol 173:487\u2013491. https:\/\/doi.org\/10.1111\/bjh.13619","journal-title":"Br J Haematol"},{"issue":"Suppl7","key":"4100_CR19","doi-asserted-by":"publisher","first-page":"vii55","DOI":"10.1093\/annonc\/mds293","volume":"23","author":"G Curigliano","year":"2012","unstructured":"Curigliano G, Cardinale D, Suter T et al (2012) Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol 23(Suppl7):vii55\u2013vii66. https:\/\/doi.org\/10.1093\/annonc\/mds293","journal-title":"Ann Oncol"},{"key":"4100_CR20","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/hon.827","volume":"25","author":"L Rigacci","year":"2007","unstructured":"Rigacci L, Mappa S, Nassi L, Alterini R, Carrai V, Bernardi F, Bosi A (2007) Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines. Hematol Oncol 25:198\u2013203. https:\/\/doi.org\/10.1002\/hon.827","journal-title":"Hematol Oncol"},{"key":"4100_CR21","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1200\/JCO.2013.49.7586","volume":"32","author":"PA Fields","year":"2014","unstructured":"Fields PA, Townsend W, Webb A, Counsell N, Pocock C, Smith P, Jack A, el-Mehidi N, Johnson PW, Radford J, Linch DC, Cunnningham D (2014) De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial. J Clin Oncol 32:282\u2013287. https:\/\/doi.org\/10.1200\/JCO.2013.49.7586","journal-title":"J Clin Oncol"},{"key":"4100_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/hon.2425","volume":"36","author":"S Luminari","year":"2018","unstructured":"Luminari S, Viel E, Ferreri AJM, Zaja F, Chimienti E, Musuraca G, Tucci A, Balzarotti M, Tani M, Salvi F, Pesce EA, Ferrari A, Liberati AM, Spadea A, Marino D, Bruno-Ventre M, Volpetti S, Bottelli C, Ravaioli E, Merli F, Spina M (2018) Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi. Hematol Oncol 36:68\u201375. https:\/\/doi.org\/10.1002\/hon.2425","journal-title":"Hematol Oncol"},{"key":"4100_CR23","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1093\/annonc\/mdq615","volume":"22","author":"L Lee","year":"2011","unstructured":"Lee L, Wang L, Crump M (2011) Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin\u2019s lymphoma: correlation of complete response, time-to-event and overall survival end points. Ann Oncol 22:1392\u20131403. https:\/\/doi.org\/10.1093\/annonc\/mdq615","journal-title":"Ann Oncol"},{"key":"4100_CR24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1136\/gutjnl-2016-312608","volume":"67","author":"LS Rigter","year":"2018","unstructured":"Rigter LS, Snaebjornsson P, Rosenberg EH, Atmodimedjo PN, Aleman BM, ten Hoeve J, Geurts-Giele WR, PALGA group, van Ravesteyn TW, Hoeksel J, Meijer GA, te Riele H, van Leeuwen FE, Dinjens WN, van Leerdam ME (2018) Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin\u2019s lymphoma treatment. Gut 67:447\u2013445. https:\/\/doi.org\/10.1136\/gutjnl-2016-312608","journal-title":"Gut"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04100-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04100-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04100-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T23:24:08Z","timestamp":1621898648000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04100-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,25]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["4100"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04100-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,25]]},"assertion":[{"value":"4 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors (TS, GD, SG, CL, MP, CDD, AM, BD, XL, VD, PI) declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with \u201cgood clinical practice\u201d and all applicable regulatory requirements, including the 2008 version of the Declaration of Helsinki. In compliance with French law, the collection and analysis of medical data by the General Cancer Registry of Poitou-Charentes has received the approval of the French regulatory authorities. Patients were informed of their data registration and given the right to deny access or to rectify their personal data. This article does not contain any studies with animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}